Last reviewed · How we verify
NCT05054712
Prevalence of Metabolic Liver Diseases in Patients With Type 1 Diabetes Mellitus
trial in Non-alcoholic Fatty Liver Disease in 250 participants. Status unknown.
1 January 2023
Quick facts
| Lead sponsor | Consorci Sanitari de l'Alt Penedès i Garraf |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 1 September 2021 |
| Primary completion | 1 January 2023 |
| Estimated completion | 1 January 2024 |
| Sites | 2 locations across Spain |
Conditions studied
- Non-alcoholic Fatty Liver Disease — all drugs for Non-alcoholic Fatty Liver Disease →
- Glycogen Hepatopathy — all drugs for Glycogen Hepatopathy →
- Type 1 Diabetes — all drugs for Type 1 Diabetes →
- Liver Diseases — all drugs for Liver Diseases →
Sponsor
Consorci Sanitari de l'Alt Penedès i Garraf — full company profile →
Who can join
Adults 18 to 100, any sex, with Non-alcoholic Fatty Liver Disease or Glycogen Hepatopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nonalcoholic fatty liver disease (NAFLD) has been extensively studied in the context of type 2 diabetes mellitus (T2D) due to its higher prevalence and its association with obesity and syndrome metabolic, a well-established risk factor for NAFLD. Although several studies have reported the accumulation of liver fat in patients with type 1 diabetes mellitus (T1D), the prevalence, etiology, and the consequences of NAFLD in patients with T1D are poorly characterized, requiring more studies in this field. In addition, liver involvement at the metabolic level in patients with T1D raises the differential diagnosis between NAFLD and glycogen hepatopathy (GH), a rare complication associated with the poorly metabolic control of diabetes and probably underdiagnosed, since the ultrasound pattern is the same than the NAFLD. The investigators have designed a cross-sectional observational study with the objective of describing the prevalence of metabolic liver diseases (NAFLD and GH) in the population of patients with T1D in the healthcare area of Hospital del Mar and Hospital de Vilafranca, as well as studying the relationship of these pathologies with the degree of metabolic control, the presence of metabolic syndrome and the presence of micro and macrovascular complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05054712
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-alcoholic Fatty Liver Disease
Currently open trials in the same condition.
- NCT07358546 — A Study of Efimosfermin Alfa in Adults With Hepatic Impairment · Phase 1 · recruiting
- NCT07335198 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a · Phase 1 · recruiting
- NCT07221188 — A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or · Phase 3 · recruiting
- NCT07221227 — A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH · Phase 3 · recruiting
- NCT07514377 — JiGenerations Health Cohort Study：Parental Exposure and Intergenerational Health in China · active not recruiting
Other Consorci Sanitari de l'Alt Penedès i Garraf trials
Trials by the same sponsor.
- NCT07278648 — High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency D · not yet recruiting
- NCT06433739 — Efficacy of a Clinical Algorithm for the Selection of Peripheral Venous Catheters · completed
- NCT07007013 — Impact of Humor Prescription on the Emotional Well-being of Patients With Medically Unexplained Symptoms: A Quasi-experi · NA · active not recruiting
- NCT07285330 — Dietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes · recruiting
- NCT06950151 — Early Detection of Chronic Kidney Disease · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05054712 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Consorci Sanitari de l'Alt Penedès i Garraf
- Last refreshed: 23 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05054712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing